Examining HSD3B1 as a possible biomarker to detect prostate cancer patients who are likely to progress on ADT

Whitney F. Handya Bernard J. Dunn School of Pharmacy, Shenandoah University, Fairfax, VA, USAView further author information

Keith T. Schmidtb Clinical Pharmacology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USAView further author information

Douglas K. Pricec Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USAView further author information

William D. Figgb Clinical Pharmacology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA;c Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USACorrespondence[email protected]
View further author information

Examining HSD3B1 as a possible biomarker to detect prostate cancer patients who are likely to progress on ADT

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Examining HSD3B1 as a possible biomarker to detect prostate cancer patients who are likely to progress on ADT

Citations (0)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date